Advanced Solid Tumors Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001)
Recruiting
  • Advanced Solid Tumors
  • Liverpool, New South Wales, Australia
  • +15 more
2022-04-07
Apr 7, 2022
A
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • AMG 994
  • AMG 404
  • Duarte, California
  • +16 more
2022-04-06
Apr 6, 2022
G
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • Grand Rapids, Michigan
  • +2 more
2022-04-07
Apr 7, 2022
N
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Recruiting
  • HRD Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • +5 more
  • Fairway, Kansas
  • +1 more
2022-04-07
Apr 7, 2022
I
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Recruiting
  • Advanced Solid Tumors
  • New Haven, Connecticut
  • +20 more
2022-04-06
Apr 6, 2022
E
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy - 2021
Completed
  • Advanced Solid Tumors
  • MSC2490484A (M3814)
  • +2 more
  • Fresno, California
  • +25 more
2022-04-06
Apr 6, 2022
K
A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • KSQ-4279
  • KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
  • Boston, Massachusetts
  • +4 more
2022-04-05
Apr 5, 2022
S
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
2022-04-04
Apr 4, 2022
S
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • Sarcoma
  • Los Angeles, California
  • +9 more
2022-04-04
Apr 4, 2022
S
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
  • Beijing, Beijing, China
  • +2 more
2022-04-01
Apr 1, 2022
S
Study of TP-3654 in Patients With Advanced Solid Tumors - 2021
Completed
  • Advanced Solid Tumors
  • Houston, Texas
  • +2 more
2022-04-04
Apr 4, 2022
S
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors - 2021
Completed
  • Advanced Solid Tumors
  • Scottsdale, Arizona
  • +4 more
2022-04-04
Apr 4, 2022
S
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors - 2020
Completed
  • Cancer
  • Advanced Solid Tumors
  • Chicago, Illinois
  • +10 more
2022-04-04
Apr 4, 2022
J
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Recruiting
  • Advanced Solid Tumors
  • Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
2022-04-02
Apr 2, 2022
A
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • La Jolla, California
  • +25 more
2022-03-23
Mar 23, 2022
S
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Recruiting
  • Advanced Solid Tumors
  • +2 more
  • Orange, California
  • +5 more
2022-03-31
Mar 31, 2022
A
A Study of ABT-165 in Subjects With Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • Scottsdale, Arizona
  • +9 more
2022-03-23
Mar 23, 2022
A
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • Denver, Colorado
  • +5 more
2022-03-21
Mar 21, 2022
A
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • Birmingham, Alabama
  • +11 more
2022-03-31
Mar 31, 2022
A
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • AMG 256
  • Duarte, California
  • +9 more
2022-03-30
Mar 30, 2022
A
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • Scottsdale, Arizona
  • +53 more
2022-03-31
Mar 31, 2022
A
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • ALKS 4230
  • ALKS 4230 + pembrolizumab
  • Denver, Colorado
  • +30 more
2022-03-29
Mar 29, 2022
A
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • New Haven, Connecticut
  • +48 more
2022-03-30
Mar 30, 2022
D
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumors
  • Debio 0123
  • Grand Rapids, Michigan
  • +3 more
2022-03-30
Mar 30, 2022